Tempus AI launches new immune efficacy test xM

Tempus AI launched an xM assay to monitor immunotherapy response in patients with advanced cancer, and its stock bucked the trend and rose higher.

Latest News

06-02
Tempus AI Stock Jumps 9% After Introducing xM for Treatment Response Monitoring
Tempus AI Stock Jumps 9% After Introducing xM for Treatment Response Monitoring
06-02
异动解读 | Tempus AI盘中大涨8.46%,推出新型免疫疗效监测方法
异动解读 | Tempus AI盘中大涨8.46%,推出新型免疫疗效监测方法
06-02
市场消息:Tempus AI推出新的免疫疗效检测方法
市场消息:Tempus AI推出新的免疫疗效检测方法
06-02
Stock Track | Tempus AI Soars 5.32% Pre-Market on Launch of Advanced Cancer Immunotherapy Monitoring Assay
Stock Track | Tempus AI Soars 5.32% Pre-Market on Launch of Advanced Cancer Immunotherapy Monitoring Assay
06-02
Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients
Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients
06-02
Tempus Introduces Xm, an Assay to Monitor Immunotherapy Response for Patients With Advanced Cancers
Tempus Introduces Xm, an Assay to Monitor Immunotherapy Response for Patients With Advanced Cancers

User Discussion

Nancy Pelosi's Tempus' AI Boost: New Product & AI Helpers

$Tempus AI(TEM)$ is up 15% after launching AI agents directly into Electronic Healthcare Records (EHRs).Why did the $Tempus AI(TEM)$ price go up?The new test is a game-changer: Tempus came out with this cool new test called xM. It’s like a super-smart way to monitor how cancer patients are responding to immunotherapy. Instead of waiting for symptoms to show up, doctors can get early insights into what’s happening with the cancer cells just by analyzing a blood sample. This helps them tweak treatments way ahead of time. The market loves this kind of innovation, so investors got excited and the stock price jumped.AI is now in hospitals: Tempus embedded over 1,000 AI helpers directly into hospital electronic heal
Nancy Pelosi's Tempus' AI Boost: New Product & AI Helpers